Latest News

 Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis
Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

April 12th 2024

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions
MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

April 10th 2024

Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis
Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis

April 4th 2024

ARCA Biopharma and Oruka Therapeutics Agree to Merger
ARCA Biopharma and Oruka Therapeutics Agree to Merger

April 3rd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.